杂合型血液净化对肾衰竭患者认知功能的影响

目的探讨在改善慢性肾衰竭患者认知功能中杂合型血液净化的疗效。方法选择收治慢性肾衰竭患者80例,所有患者均匀2017年1月-2019年5月在本院接受治疗,按照治疗方法分为实验组(n=40)和对照组(n=40)。对照组接受血液透析治疗,实验组接受杂合型血液净化治疗,观察两组治疗效果及认知功能。结果实验组血红蛋白(90.2±12.0)g/L、转铁蛋白(3.2±0.3)g/L、血清前白蛋白(297.6±56.1)mg/L、血清白蛋白(38.9±5.1)g/L,明显优于对照组的(58.4±9.9)g/L、(2.1±0.2)g/L、(150.1±36.2)mg/L、(29.3±4.4)g/L(t=12.93,P=0.00;t=19.30,P=0.00;t=13.92,P=0.00;t=9.01,P=0.00)。实验组记忆力评分(3.1±0.3)分、定向力评分(4.2±1.1)分、语言能力评分(4.1±1.2)分、注意力评分(3.9±1.1)分、总体评分(29.2±5.0),均明显高于对照组的(1.2±0.1)分、(2.1±0.3)分、(2.2±1.3)分、(2.1±0.3)分、(27.1±2.6)分(t=38.00,P=0.00;t=11.65,P=0.00;t=6.79,P=0.00;t=9.99,P=0.00;t=2.36,P=0.01)。实验组并发症发生率5.0%,显著低于对照组的20.%(χ^2=4.11,P=0.43)。结论针对慢性肾衰竭患者实施杂合型血液净化治疗,可明显提升治疗效果,改善患者认知功能。

Effect of Heterozygous Blood Purification on Cognitive Function in Patients With Renal Failure

Objective To investigate the efficacy of heterozygous blood purification in improving cognitive function of patients with chronic renal failure. Methods 80 patients with chronic renal failure were selected and treated in our hospital from January 2017 to May 2019. The patients were divided into experimental group(n=40) and conventional group(n=40) according to the treatment method. The conventional group received hemodialysis treatment, and the experimental group received heterozygous blood purification treatment. The therapeutic effect and cognitive function of the two groups were observed. Results hemoglobin(90.2±12.0) g/L, transferrin(3.2±0.3) g/L, serum proalbumin(297.6±56.1) mg/L, serum albumin(38.9±5.1) g/L in the experimental group were significantly better than those in the conventional group(58.4±9.9) g/L,(2.1±0.2) g/L,(150.1±36.2) mg/L,(29.3±4.4) g/L(t=12.93, P=0.00).(t=19.30, P=0.00;t= 13.92, P=0.00;t=9.01, P=0.00). Memory score(3.1± 0.3), orientation score(4.2±1.1), language ability score(4.1±1.2), attention score(3.9±1.1), and overall score(29.2±5.0) in the experimental group were significantly higher than those in the conventional group(1.2±0.1),(2.1±0.3),(2.2±1.3),(2.1±0.3), and(27.1±2.6)(t=38.00, P=0.00;t=11.65, P=0.00;t=6.79, P=0.00;t=9.99, P=0.00;t=2.36, P=0.01). The incidence of complications in the experimental group was 5.0%, significantly lower than that in the conventional group 20.0%(χ^2=4.11, P=0.43). Conclusion heterozygous blood purification therapy for patients with chronic renal failure can significantly improve the therapeutic effect, improve the cognitive function of patients.